# A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis

> **NCT01712399** · PHASE2 · TERMINATED · sponsor: **MedImmune LLC** · enrollment: 409 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Mavrilimumab 100 mg

## Key facts

- **NCT ID:** NCT01712399
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01-28
- **Primary completion:** 2015-12-30
- **Final completion:** 2015-12-30
- **Target enrollment:** 409 (ACTUAL)
- **Why stopped:** The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations.
- **Last updated:** 2017-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712399, "A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01712399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*